GC 008T
Alternative Names: CRISPR-engineered CAR-T cells - Gracell Biotechnology; GC008t; Mesothelin-directed CAR-T cells - Gracell BiotechnologyLatest Information Update: 26 Feb 2024
At a glance
- Originator Gracell Biotechnology
- Developer Chinese PLA General Hospital; Gracell Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 22 Feb 2024 Gracell Biotechnology has been acquired by AstraZeneca
- 28 Jan 2022 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in China (Parenteral, Infusion)
- 29 May 2020 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)